Mirdametinib (PD0325901) is a selective, non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM in cell-free trials, and its inhibition of ERK1 and ERK2 phosphorylation is about 500 times stronger than that of CI-1040. Phase 2.

 

Brand: BCM

 

Melting Point: 112 ~ 114°C

 

pKa: 13.45±0.20(Predicted)

 

Optical activity: [α]/D -1.8 to -3.5°, c = 1 mg/mL in methanol

 

Solubility: Soluble in DMSO and Ethanol. Insoluble in Water.

 

Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO or ethanol may be stored at -20° for up to 3 months.

 

InChIKey: SUDAHWBOROXANE-SECBINFHSA-N

 

Attribute
[CAS No.]	391210-10-9
[MDL No.]	MFCD08435926
[Formula]	C16H14F3IN2O4
[Molecular]	482.191
[Chem Name]	(R)-N-(2,3-Dihydroxypropoxy)-3,4-difluoro-2-((2-fluoro-4-iodophenyl)amino)benzamide
[Synonym]	PD0325901; Mirdametinib
[Storage]	Sealed in dry. Stored at 2-8 °C
[Form]	White to off-white solid

Goods Tag